Adicet Bio, Inc. (ACET)
Nasdaq · Healthcare · Biotechnology
$6.47−0.46%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $60.6M
- 52-week range
- $6.01 – $17.44
- 52-week change
- −52.37%
- EPS (trailing)
- −$10.42
- Analyst rating
- 1.0 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Net income
- −$117M
- Diluted EPS
- −$16.95
- Free cash flow
- −$97.0M
From the company’s annual report on SEC EDGAR.
About Adicet Bio, Inc.
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
Headquarters: Boston, United States · 102 employees · adicetbio.com